-
ALS Stem Cell Trial Expanding to U-M
Neuralstem’s NSI-566/ALS trial expanding to include University of Michigan, in addition to Emory, is the focus of this report on FDA approval of the Phase II trial.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.